London Daily

Focus on the big picture.
Sunday, Sep 28, 2025

Why the Pfizer-BioNTech vaccine is no cure for all coronavirus ills

Why the Pfizer-BioNTech vaccine is no cure for all coronavirus ills

Amid the excitement over a vaccine said to be 90 per cent effective, questions remain over virus mutations, people refusing to take it and the problem of storing it at -80 degrees.

The coronavirus vaccine developed by Pfizer and BioNTech has raised hopes for the end of the pandemic after the interim result of trials showed 90 per cent effectiveness, but questions remain about safety, distribution and its precise effect on the virus.

Before the vaccine is approved for use by health authorities around the world, it will have to meet certain safety requirements that vary by jurisdiction.
In the United States, the Food and Drug Administration is requiring manufacturers to produce safety data on half of subjects for two months after their second dose of the vaccine before it can be approved for emergency use.

Pfizer has said it expects to reach this by the third week of November, and has reported no serious adverse reactions in the nearly 40,000 trial participants who have received two doses of the vaccine.

The US multinational believes it can produce 50 million vaccine doses this year and up to 1.3 billion doses in 2021.

Ian Frazer, a professor at the University of Queensland who co-invented the human papillomavirus vaccine, said there was still a “small risk of unexpected safety issues” and that some people might refuse to take it.

“It depends on their risk level – I’d have it if working in a hospital,” he said. “I’d guess that most young people will think twice in Australia
where there’s now no virus.”

Terry Nolan, a vaccine expert at the University of Melbourne, said that while he found safety concerns about such a rapidly developed vaccine “understandable”, it would be vital for the public to get on board with mass immunisation.

“Unless there are very high levels of protection of the community there’s very little hope of getting anything near herd immunity,” Nolan said.

Apart from safety, potential complications could include virus mutations that could impact the vaccine’s effectiveness over time.

Health authorities across the world have indicated that the first doses of a successful vaccine will go to high-risk groups, such as frontline health care workers, employees in aged care facilities, and the elderly.

Frazer predicted the general public would have to wait a “year or longer” until they would have access to the vaccine.

Nolan suggested a less conservative time frame, saying he expected a vaccine to be available “well before” a year’s time.

He said Pfizer’s apparent breakthrough indicated that other vaccines based on the same principles would also be effective, which would be a “matter of comfort for the world that the supply from a number of manufacturers is very likely to be there”.

Nearly a dozen vaccines are in large-scale, human trials – known as phase 3 trials – including candidates developed in the US, China, Russia and Britain.

In August, Russia became the first country to announce the approval of a vaccine before the completion of extensive human trials, prompting widespread scepticism and criticism among scientists and medical professionals.

The Russian government later said the approval of the vaccine, developed by the Moscow-affiliated Gamaleya Institute, was “conditional” on the results of phase 3 trials. Last month, Russian President Vladimir Putin announced the approval of a second vaccine before phase 3 trials had even begun.


Demonstrators with a giant syringe protest against China's Sinovac vaccine.


China has approved the limited use of three vaccines for some groups such as the military, including the Sinovac Biotech vaccine, trials for which were briefly halted by Brazilian authorities on Monday following an “adverse event”. Brazil’s health authority restarted the trials on Wednesday after it was confirmed that a volunteer had died from suicide, not an adverse reaction to the vaccine.

Chinese health officials have reported no adverse side effects from the hundreds of thousands of doses administered through the emergency use listing of the Sinovac vaccine and vaccines by CanSino Biologics and the Wuhan Institute of Biological Products.

Governments around the world have invested huge sums into securing multiple different vaccines ahead of time, with the cost per dose ranging from US$32-US$37 for the Moderna vaccine to a few dollars for AstraZeneca’s offering. The US government paid US$1.5 billion to Moderna alone to secure 100 million doses of its candidate.

The buying up of potential vaccines by rich countries has raised concerns about their availability in the developing world.


As of September, developed countries including the US, Britain , Australia and Japan had secured more than half of the 5.3 billion doses allocated in supply deals inked by AstraZeneca, the Gamaleya Institute, Moderna, Pfizer and Sinovac, according to an analysis by Ofxam.

In response to such concerns, the global collaboration Covax has raised more than US$2 billion from nearly 100 rich nations to purchase and distribute vaccines among poorer countries.

Distribution poses a major challenge due to the particular storage requirements of the vaccine, particularly in lower-income countries with less developed infrastructure. Unlike most vaccines which can be stored in a normal refrigerator, the Pfizer/BioNTech vaccine must be kept at -80 degrees Celsius. Freezers capable of maintaining such temperatures are uncommon even at major hospitals in developed countries. Pfizer has said it plans to use dry ice to transport the vaccine by land and air to distribution centres around the world, a daunting logistical feat.

“Are there sufficient ultra-low [temperature] refrigerators at vaccination sites?” asked John Siu Lun Tam, a vaccination expert at the Hong Kong Polytechnic University. “How would we know if the ‘ultra-low cold chain’ had been kept and that the vaccine you get is not inactivated?

“The complete vaccinations process requires two injections,” Tam said. “There will be a logistics issue about how to make sure people actually get two doses.”

A big unknown remains the vaccine’s effectiveness in stopping transmission of the virus. While the Pfizer/BioNTech candidate has shown major promise in preventing sickness, there is as yet little indication it is effective at stopping the spread of infection among people.

“The animal studies which have been done ahead of time so far, including some challenge studies in monkeys, suggest that this class of vaccine may not prevent transmission,” Nolan said.

That could result in authorities significantly prolonging their pandemic restrictions. Plans for unrestricted international travel for those with a “health passport” showing they have been vaccinated, for example, might have to wait.

“The whole quarantine business is very, very difficult,” Nolan said. “To have completely free travel for those who have, say, a passport, would be what we’re hoping to happen, but we can’t at the moment guarantee that would happen.”

Newsletter

Related Articles

0:00
0:00
Close
U.S. Defense Chief Orders Sudden Summit of Hundreds of Generals and Admirals
Global Cruise Industry Posts Dramatic Comeback with 34.6 Million Passengers in 2024
Trump Claims FBI Planted 274 Agents at Capitol Riot, Citing Unverified Reports
India: Internet Suspended in Bareilly Amid Communal Clashes Between Muslims and Hindus
Supreme Court Extends Freeze on Nearly $5 Billion in U.S. Foreign Aid at Trump’s Request
Archaeologists Recover Statues and Temples from 2,000-Year-Old Sunken City off Alexandria
China Deploys 2,000 Workers to Spain to Build Major EV Battery Factory, Raising European Dependence
Speed Takes Over: How Drive-Through Coffee Chains Are Rewriting U.S. Coffee Culture
U.S. Demands Brussels Scrutinize Digital Rules to Prevent Bias Against American Tech
Ringo Starr Champions Enduring Beatles Legacy While Debuting Las Vegas Art Show
Private Equity’s Fundraising Surge Triggers Concern of European Market Shake-Out
Colombian President Petro Vows to Mobilize Volunteers for Gaza and Joins List of Fighters
FBI Removes Agents Who Kneeled at 2020 Protest, Citing Breach of Professional Conduct
Trump Alleges ‘Triple Sabotage’ at United Nations After Escalator and Teleprompter Failures
Shock in France: 5 Years in Prison for Former President Nicolas Sarkozy
Tokyo’s Jimbōchō Named World’s Coolest Neighbourhood for 2025
European Officials Fear Trump May Shift Blame for Ukraine War onto EU
BNP Paribas Abandons Ban on 'Controversial Weapons' Financing Amid Europe’s Defence Push
Typhoon Ragasa Leaves Trail of Destruction Across East Asia Before Making Landfall in China
The Personality Rights Challenge in India’s AI Era
Big Banks Rebuild in Hong Kong as Deal Volume Surges
Italy Considers Freezing Retirement Age at 67 to Avert Scheduled Hike
Italian City to Impose Tax on Visiting Dogs Starting in 2026
Arnault Denounces Proposed Wealth Tax as Threat to French Economy
Study Finds No Safe Level of Alcohol for Dementia Risk
Denmark Investigates Drone Incursion, Does Not Rule Out Russian Involvement
Lilly CEO Warns UK Is ‘Worst Country in Europe’ for Drug Prices, Pulls Back Investment
Nigel Farage Emerges as Central Force in British Politics with Reform UK Surge
Disney Reinstates ‘Jimmy Kimmel Live!’ after Six-Day Suspension over Charlie Kirk Comments
U.S. Prosecutors Move to Break Up Google’s Advertising Monopoly
Nvidia Pledges Up to $100 Billion Investment in OpenAI to Power Massive AI Data Center Build-Out
U.S. Signals ‘Large and Forceful’ Support for Argentina Amid Market Turmoil
Nvidia and Abu Dhabi’s TII Launch First AI-&-Robotics Lab in the Middle East
Vietnam Faces Up to $25 Billion Export Loss as U.S. Tariffs Bite
Europe Signals Stronger Support for Taiwan at Major Taipei Defence Show
Indonesia Court Upholds Military Law Amid Concerns Over Expanded Civilian Role
Larry Ellison, Michael Dell and Rupert Murdoch Join Trump-Backed Bid to Take Over TikTok
Trump and Musk Reunite Publicly for First Time Since Fallout at Kirk Memorial
Vietnam Closes 86 Million Untouched Bank Accounts Over Biometric ID Rules
Explosive Email Shows Sarah Ferguson Begged Forgiveness from Jeffrey Epstein After Taking His Money
Corrupt UK Politician Ed Davey Demands Elon Musk’s Arrest for Supporting Democracy
UK, Canada, and Australia Officially Recognise Palestine in Historic Shift
Alibaba Debuts Open-Source Deep Research Agent with Benchmarks Rivaling OpenAI
Marcos Faces Legacy-Defining Crisis as Flood Projects Scandal Sparks Massive Tide of Protests
China’s Micro-Drama Boom Turns Stalled Real Estate Projects into Lavish Film Sets
New Eye Drops Show Promise in Replacing Reading Glasses for Presbyopia
'Company Got 5,189 H-1B Visas, Then Laid Off 16,000 Americans': US Defends New $100,000 H-1B Visa Fee
Golf legend tells Omar she should be 'sent back to Somalia' after her Kirk comments
EU Set to Bar Big Tech from New Financial Data Access Scheme
China Bans Livestreaming and AI in Religion Amid Crackdown on Shaolin Temple Scandal
×